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Objectives: Allografts offer many advantages over prosthetic valves, but
allograft durability varies considerably. Methods: From 1969 through
1993, 618 patients aged 15 to 84 years underwent their first aortic valve
replacement with an aortic allograft. Concomitant surgery included
aortic root tailoring (n = 58), replacement or tailoring of the ascending
aorta (n = 56), and coronary artery bypass grafting (n = 87). Allograft
implantation was done by means of a “freehand” subcoronary tech-
nique (n = 551) or total root replacement (n = 67). The allografts were
antibiotic sterilized (n = 479), cryopreserved (n = 12), or viable (un-
processed, harvested from brain-dead multiorgan donors or heart
transplant recipients, n = 127). Maximum follow-up was 27.1 years.
Results: Thirty-day mortality was 5.0%, and crude survival was 67%
and 35% at 10 and 20 years. Ten- and 20-year rates of freedom from
complications were as follows: endocarditis, 93% and 89%; primary tis-
sue failure, 62% and 18%; and redo aortic valve replacement, 81% and
35%. Multivariable Cox analyses identified several valve- and proce-
dure-related determinants: rising allograft donor age and antibiotic-
sterilized allograft for mortality; donor more than 10 years older than
patient for endocarditis; rising donor age minus patient age, rising
implantation time (from harvest to aortic valve replacement), and donor
age more than 65 years for tissue failure; and rising donor age minus
patient age, young patient age, rising implantation time, and subcoro-
nary implantation preceded by aortic root tailoring for redo aortic valve
replacement. Estimated 10- and 20-year rates of freedom from tissue
failure for a 70-year-old patient with a viable valve from a 30-year-old
donor and no other risk factors were 91% and 64%; the figures were
71% and 20% if the donor age was 65 years. The rates of freedom from
tissue failure for a 30-year-old patient with a 30-year-old donor were
82% and 39%; the figures were 49% and 3% with a 65-year-old donor.
Beneficial influences of a viable valve were largely covered by short har-
vest time (no delay for allografts from brain dead organ donors or heart
transplant recipients) and short implantation time. Conclusions: Primary
allograft aortic valve replacement can give acceptable results for up to
25 years. The late results can be improved by the use of a viable allo-
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T he allograft aortic valve was the first successfulreplacement valve used in the aortic position,1 and
its advantages suggested in early series1-3 still stand:
excellent hemodynamic function, low thrombogenicity,
and resistance to infection. A few centers have consis-
tently used the allograft since the 1960s,4-8 and it still is
the valve of choice at our center. A current growing
interest in stentless xenografts in aortic valve replace-
ment (AVR) rests to a significant degree on accumulat-
ed experience with the allograft.
The main concern regarding the allograft is its dura-
bility, which to some degree is determined by source
(living or diseased donor)5,7,9 and methods of steriliza-
tion and preservation.10 Furthermore, as with any other
biologic valve, primary (degenerative) tissue failure of
the allograft accelerates more than 10 years after the
operation, indicating that follow-up well beyond 15
years is needed to judge the true freedom from failure
at 10 and 15 years.
The aim of the present study was to judge the true
behavior of the allograft after first-time AVR in a large
homogeneous patient series with a follow-up exceeding
25 years, that is, beyond the high hazard phase for fail-
ure between 10 and 20 years after the operation.
Furthermore, we wanted to identify independent deter-
minants of outcome related to the allograft and the sur-
gical procedure.
Patients and methods
During the 25-year period 1969 through 1993, 618 patients
aged 15 to 84 (mean 51 years), who underwent their first AVR
at Harefield Hospital, had an aortic allograft implanted.
Patients with concomitant surgical procedures on the aortic
root or the ascending aorta, as well as coronary artery bypass
grafting, were included; any other surgical procedure and age
of 14 years or younger served as exclusion criteria. The allo-
graft was chosen irrespective of age, poor left ventricular
function, and emergency operation, subject only to availabil-
ity. The present 618 patients constitute 74% of all (with sim-
ilar inclusion/exclusion criteria) who had a primary AVR per-
formed by or under the service of one senior surgeon. The
primary indication for surgery included aortic stenosis (n =
285), aortic regurgitation (n = 146), combined stenosis and
regurgitation (n = 100), active endocarditis (n = 52), and aor-
tic aneurysm or dissection with aortic regurgitation (n = 33)
or stenosis (n = 2). Heart catheterization was performed
before the operation in the majority of patients, combined
with echocardiography in 177, while 43 had an echocardio-
gram exclusively. Coronary angiography was performed in
292 patients, of whom 87 had significant coronary artery dis-
ease (luminal diameter narrowing ‡ 50% of at least one major
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Table I. Preoperative patient profile
Demographic data
Age (y) 51 ± 16 (15-84)
≤49 39% (242)
50-69 54% (333)
‡ 70 7% (43)
Male sex 70% (430)
Non-UK residency 9% (55)
Nonwhite race 11% (70)
Clinical/paraclinical data
Etiology
Degenerative 17% (108)
Bicuspid 36% (222)
Rheumatic 13% (82)
Congenital 11% (67)
Previous endocarditis 4% (24)
Active endocarditis 8% (52)
Marfan syndrome 3% (17)
IMN/syphilis/CTD 6% (33)
Other 2% (13)
NYHA class
I 3% (29)
II 19% (117)
III 62% (383)
IV 16% (98)
Limiting symptom
Dyspnea 67% (416)
Angina 20% (122)
Syncope 4% (27)
Other 6% (33)
Clinical left ventricular failure 32% (198)
Valve disease
Stenosis 47% (291)
Regurgitation 36% (224)
Combination 17% (103)
Cardiothoracic index 0.54 ± 0.06 (0.39-0.78)
Kidney failure 5% (31)
Hypertension 9% (56)
Previous myocardial infarction 9% (56)
Diabetes mellitus 3% (18)
Arrhythmia* 4% (27)
Bundle branch block 8% (48)
Atrioventricular block, grade 1-3 6% (36)
Ventricular ectopia† 3% (18)
Data are mean ± SD (range) or percent (number). IMN, Idiopathic medial
necrosis; NYHA, New York Heart Association; CTD, connective tissue disease.
*Atrial fibrillation or paced rhythm.
†More than 10% of beats in the electrocardiogram. 
graft, by matching patient and donor age, and by more liberal use of
free root replacement with re-implantation of the coronary arteries
rather than tailoring the root to accommodate a subcoronary implan-
tation. (J Thorac Cardiovasc Surg 1999;117:77-91)
epicardial artery or a first branch). Clinical left ventricular
failure was recorded in case of pulmonary edema or vascular
congestion within a year before the operation,11 kidney fail-
ure if the S-creatinine concentration was elevated above the
reference level for our laboratory in at least two preoperative
blood samples, systemic hypertension in case of current or
previous medical treatment, and diabetes mellitus in case of
treatment with oral antidiabetic drugs or insulin. The preop-
erative patient profile is given in Table I.
Allograft data. A total of 483 aortic allografts were
obtained during routine autopsies. The valves were dissected
under sterile conditions, sterilized in antibiotic solutions,9,12
and either cryopreserved (n = 10)12 or kept at 4oC in tissue cul-
ture medium with antibiotics (n = 473)9 until insertion. The
remaining 135 allografts were harvested from brain dead mul-
tiorgan donors (n = 15) or heart transplant recipients (n = 120).
Eight of these valves were antibiotic sterilized (n = 6) or cry-
opreserved (n = 2), and 127 were unprocessed viable allo-
grafts5: they were kept at 4oC in tissue culture medium
(Medium 199 with Earle’s salts, ICN Biomedicals, High
Wycombe, Bucks, United Kingdom) containing extremely
small doses of penicillin and inserted at the earliest opportuni-
ty. A detailed allograft profile is given in Table II. The viable
allografts were first used in 1980; the 127 viable allografts con-
stituted 64% of the 199 allografts used from 1980 to 1993, the
limiting factor being availability of a living donor. Viable
valves and antibiotic-sterilized allografts differed in terms of
harvest time, but also as regards donor age, donor and patient
age difference, and implantation time (Table II). Before 1980,
20 (4.8%) of 419 patients had a full root replacement compared
with 47 (23.6%) of 199 patients operated on in the period 1980
to 1993 (P < .0001). As many as 38 (57%) of the 67 root
replacements but only 89 (16%) of the 551 subcoronary allo-
graft implantations were done with a viable valve (P < .0001).
Surgical technique. Standard total cardiopulmonary
bypass with either continuous or intermittent coronary perfu-
sion (n = 486) or crystalloid (standard St Thomas Hospital
solution) cardioplegic cardiac arrest (n = 132) was used. In
case of a subcoronary implantation, the allograft was scal-
loped according to the anatomy of the aortic root and insert-
ed with a “2-line freehand” technique as previously
described3 (n = 551). In 58 patients, an aortic root tailoring or
widening with a gusset of autologous pericardium was nec-
essary to accommodate a subcoronary implantation. A full
root replacement with reimplantation of the coronary ostia
was performed in the remaining 67 patients as previously
described.13 The latter technique was preferred especially in
patients with mismatch in size or shape between the patient’s
aortic root and the allograft and in patients with aortic root
disease.14,15 Surgical procedures on the ascending aorta
included partial replacement with the allograft aorta in case
of proximal disease (n = 23), complete replacement with a
preclotted Dacron prosthesis (n = 26), or tailoring (n = 7).
Coronary bypass was performed in 87 patients (1-4 grafts,
mean 1.7). A total of 188 patients (30.4%) had at least 1 of
these associated surgical procedures (n = 136) or were oper-
ated on because of active endocarditis (n = 52). A summary
of the surgical procedures is given in Table III. A total of 53
patients received life-long anticoagulant therapy (or
antiplatelet treatment) with warfarin (n = 22) or acetylsali-
cylic acid and dipyridamole (n = 31) because of chronic atrial
fibrillation, previous stroke, or coronary disease.
Follow-up. All patients attended an outpatient clinic
appointment 4 to 7 weeks after the operation, and those liv-
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Table II. Allograft profile
Viable Antibiotic sterilized 
(n = 127) (n = 491)* P value
Donor
Cadaver 0 98% (483)
Transplant recipient 88% (112) 2% (8) <.0001
BD multiorgan donor 12% (15) 0
Donor age (y) 44 ± 11 (14-65) 52 ± 12 (14-77) <.0001
Donor minus patient age (y) –5 ± 19 (–47 to 37) 1 ± 18 (–61 to 57) .002
Gender
Patient-donor match 69% (87) 72% (353) .45
Patient-donor mismatch 31% (40) 28% (138)
Harvest time (h)† 0 40 ± 22 (0-102) .0001
Implantation time (h)‡ 48 (2-720) 168 (12-1080) .002
≤48 49% (62) 22% (110)
49-96 31% (31) 19% (92)
‡ 97 20% (25) 59% (289)
Year of operation 1990 (1980-1993) 1974 (1969-1993) <.0001
1969-1979 0 85% (419)
1980-1989 46% (59) 6% (29)
1990-1993 54% (68) 9% (43)
Data are percent of patients (number), mean ± SD (range), or median (range). AB, Antibiotic solution, see text; BD, brain dead.
*Includes 12 cryopreserved valves, see text.
†From death of donor to harvest of valve; 0 when harvest from living donor (transplant recipient and brain dead multiorgan donor).
‡From harvest to operation.
ing in England additionally attended annual outpatient clinic
appointments at our hospital. Since 1978 the outpatient clinic
investigation has included an echocardiogram. From August
1995 through April 1997, we interviewed (mailed question-
naire and telephone) all patients who were still alive, and we
contacted the general practitioner (mailed questionnaire and
telephone) of all patients (living as well as deceased). All hos-
pital contacts were checked. At termination of the study, 31
patients had died within 30 days after the operation (early
mortality), 263 patients had died later, 294 patients were still
alive, and 30 (4.9%) could not be traced. A total of 6229
patient-years (mean 10.1, maximum 27.1 years; maximum
17.1 years for the viable allografts) had been accumulated.
Follow-up with an allograft in place (first or redo) totaled
5719 patient-years, which was used in the analyses of valve-
related complications; that is, a patient was censored at the
time of a redo AVR if the replacement valve was a xenograft
or mechanical prosthesis.
Valve-related complications. Registration of valve-related
complications followed internationally accepted guidelines16
as previously detailed.5,17,18 Embolism was recorded if a sys-
temic arterial vascular event could not be proved to be throm-
botic or hemorrhagic. Bleeding was recorded if the patient
received anticoagulant (or antiplatelet) treatment. Embolic
and hemorrhagic events were recorded as minor if symptoms
subsided within 48 hours (eg, transitory cerebral ischemia) or
as major if they did not. In addition, we recorded non–valve-
related strokes, that is, major cerebral events proven to be
thrombotic or proven to be hemorrhagic in patients who did
not receive anticoagulant treatment. Primary tissue failure (n
= 258) of the allograft was recorded in case of significant
regurgitation (at least grade 3/4) or stenosis (gradient ‡ 35
mm Hg) at aortic root angiography (n = 60) or Doppler
echocardiography (n = 99), discovered during redo AVR (n =
52) or postmortem examination (n = 21), or when the follow-
ing clinical criteria were fulfilled: the presence of a diastolic
murmur, a wide pulse pressure (>50 mm Hg), increased car-
diothoracic index (>0.50), and increasing left ventricular
hypertrophy and strain pattern in the electrocardiogram,4 all
in the absence of infectious endocarditis.
Statistical analysis. All analyses were computerized by
means of the BMDP Dynamic version 7.0 software package
(BMDP Software, Los Angeles, Calif).19 Simple comparisons
were done with the use of a nonpaired t test, a 1-way analy-
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Table III. Surgical profile and early* mortality
Surgical profile Early* mortality 
(all 618 patients) (clean procedure or combination†‡§) P valueII
Allograft valve procedure
Subcoronary implantation 80% (493) 4.1% (17/415†)
Subcoronary with root tailoring 9% (58) 4.0% (2/50†) .99
Root replacement 11% (67) 4.1% (2/49†)
Coronary artery bypass
No 86% (531) 3.9% (17/436†) .60
Yes 14% (87) 5.1% (4/78†)
Ascending aorta procedure
No 91% (562) 4.1% (21/514‡)
Replacement with allograft 4% (23) 0% (0/22‡)
Replacement with Dacron prosthesis 4% (26) 20.0% (5/25‡) .002
Tailoring 1% (7) 0% (0/5‡)
Operation for active endocarditis
No 92% (566) 4.1% (21/514§)
Yes 8% (52) 9.6% (5/52) .06
Crossclamp time (min) 83 ± 21 (34-200)
≤90 min 67% (413) 3.1% (13/413)
>90 min 33% (205) 8.8% (18/205) .003
ECC time (min) 102 ± 35 (46-288)
≤150 min 91% (560) 4.1% (23/560)
>150 min 9% (58) 13.8% (8/58) .001
Myocardial preservation
Coronary perfusion¶ 79% (486) 5.6% (27/486)
Crystalloid cardioplegia 21% (132) 3.0% (4/132) .25
Data are mean ± SD (range) or percent (number). ECC, extracorporeal circulation. 
*Death within 30 days after the operation.
†Early death/No. of patients excluding those operated on for active endocarditis or with ascending aorta procedure.
‡Early deaths/No. of patients excluding those operated on for active endocarditis.
§Early death/No. of patients excluding those with ascending aorta procedure.
IIOf mortality comparison.
¶Intermittent or continuous.
sis of variance, or a Pearson c 2 test as appropriate. Cum-
ulative survival and event-freedom curves were made by
means of the Kaplan-Meier product-limit method, and differ-
ences between curves were tested with a log-rank and a
Gehan test. Multivariable analysis of early mortality was
done with a stepwise logistic regression analysis, whereas
late mortality and valve-related complications were tested
with a Cox proportional hazards regression analysis. All vari-
ables of Tables I to III were tested in the analyses. The mul-
tivariable tests were done by means of a comprehensive for-
malized analysis sequence, which has been previously
described.11,18 The odds ratio was calculated18 for each inde-
pendent risk factor to indicate the increase of risk associated
with the risk level of a dichotomous risk factor or the risk
increase relative to 1 unit increase of a quantitative risk fac-
tor. Estimated event-freedom curves for subgroups of patients
were made by means of the Cox model; this method re-uses
the common underlying event-freedom function of all 618
patients for each subgroup estimate.18,19 Cumulative survival
and event freedom, as well as linearized incidences, are given
with ± 1 standard error (SE); 95% confidence limits (95%
CL) were identified by the “± 2 SE” cutoff points.20
Quantitative data are given as mean ± standard deviation
(SD).
Results
Early and late mortality. The causes of deaths are
given in Table IV; cardiac causes dominated and only
15% of late deaths could be related to the allograft.
Early mortality. By univariate analysis, early mortal-
ity (5.0%) was unrelated to allograft procedure and
associated coronary bypass grafting. It was higher for
patients who had the ascending aorta replaced with a
Dacron prosthesis, and it tended to be higher for those
operated on because of active endocarditis (Table III).
The independent risk factors for early mortality are
shown in Table V.
Long-term survival. Crude survival of all 618
patients is shown in Fig 1. Patients with a viable allo-
graft had a better overall survival than those with an
antibiotic-sterilized allograft (Fig 2). Allograft proce-
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Table IV. Causes of death
Early* Late 
(n = 31) (n = 263)
Cardiac 74% (23) 55% (144)
Low cardiac output/ (15) (84)
congestive heart failure
Myocardial infarction (4) (44)
Arrhythmia (4) (8)
Sudden unexpected (0) (8)
Valve related† 3% (1) 15% (39)
Postoperative bleeding 3% (1) 0%
Other 20% (6) 30% (80)
Data are percent (number).
*Death within 30 days after the operation.
†See Table VII.
Table V. Independent determinants for early mortality
Risk factor b (SE) OR P value
Kidney failure 2.37 (0.50) 10.7 .0001
Replacement of ascending 1.77 (0.59) 5.9 .007
aorta with prosthesis
Bundle branch block 1.44 (0.48) 4.2 .006
Patient age ‡ 70 y 1.38 (0.52) 4.0 .01
Crossclamp time ‡ 90 min 0.96 (0.41) 2.6 .02
b, Regression coefficient; SE, standard error; OR, odds ratio (see text).
Fig 1. Cumulative survival of all 618 patients. Cumulative survivals ± 1 SE are given at 5-year intervals. Numbers
of patients at risk are given at 5-year intervals above the abscissa.
dure also influenced survival, with the most favorable
results related to root replacement (Fig. 3). The final
Cox model for late mortality is given in Table VI.
Donor age and patient age were both directly related to
mortality independently of one another and with differ-
ent strength. A viable allograft independently reduced
the late death rate. The beneficial influence of residen-
cy outside the United Kingdom probably was related to
the fact that our foreign patients were a highly selected
group who were self-funding and who represented a
fairly high socioeconomic status.
Valve-related complications. The complications
observed during follow-up are summarized in Table
VII, and the cumulative event-freedom curves are
depicted in Fig. 4. There were no paravalvular leakages
or other complications.
Bleeding and embolism. The incidence of anticoagu-
lant-related bleeding episodes was negligible, whereas
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Fig 2. Cumulative survival in relation to type of allograft (see text). AB, Antibiotic sterilized (the group includes
12 patients who received a cryopreserved allograft). Cumulative survivals ± 1 SE (number of patients at risk) are
given at 5-year intervals.
Fig 3. Cumulative survival in relation to allograft procedure: Full root replacement with reimplantation of the
coronary ostia; subcoronary implantation of a scalloped allograft with 2-line suturing technique; and subcoronary
implantation preceded by tailoring of the aortic root in patients operated on for chronic valve disease (aortic
stenosis, regurgitation, or a combination), excluding patients operated on primarily because of endocarditis or
ascending aortic aneurysm or dissection. Cumulative survivals ± 1 SE (number of patients at risk) are given at 5-
year intervals.
there were 82 embolic episodes (vascular events that
could not be proven to be hemorrhagic or thrombotic)
in 66 patients; 76% (n = 62) of the events were cerebral
and 67% (n = 55) were classified as minor (Table VII).
The independent determinants for embolism (Table
VIII) included long harvest time (for a cadaver valve;
see Table II).
Background incidence of stroke. Using tabulated age-
and sex-stratified incidences of a United Kingdom pop-
ulation study,21 we estimated the background incidence
of first stroke as previously described.22 The incidence
of a background population with a sex and age compo-
sition like those of the present 618 patients was
0.25%/pt-y. Twenty of the present patients had a stroke
(anticoagulant-related bleeding, n = 2; embolic stroke,
n = 13 [Table VII]; non–valve-related stroke, n = 5),
giving a patient incidence of 0.35%/pt-y (95% CL:
0.19%-0.51%/pt-y). With or without the age risk factor,
415 patients of the present group with none of the other
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Fig. 4. Cumulative freedom from valve-related complications in all 618 patients; see Table VII and text. AC,
Anticoagulant (warfarin, 22 patients; acetylsalicylic acid and dipyridamole, 31 patients; the remaining 565
patients did not receive any anticoagulant treatment). Cumulative freedoms ± 1 SE are given at 10, 15, 20, and
25 years. Numbers of patients at risk are given in parentheses for thromboembolism and tissue failure.
Table VI. Independent determinants for late mortality
b (SE) OR P value
Patient age* 0.03 (0.005) 1.36† <.0001
Male sex 0.63 (0.15) 1.87 <.0001
Cardiothoracic index* 3.08 (1.06) 1.36‡ .004
Crossclamp time* 0.008 (0.003) 1.27§ .004
Donor age* 0.015 (0.006) 1.16† .009
Viable allograft –0.66 (0.27) 0.52 .01
Non-UK residency –0.78 (0.37) 0.45 .03
NYHA class III-IV 0.35 (0.17) 1.42 .04
Marfan syndrome 0.40 (0.19) 1.49 .04
b, Regression coefficient; SE, standard error; OR, odds ratio (see text);
NYHA, New York Heart Association.
*Entered with continuous value.
†For an age increase of 10 years.
‡For a cardiothoracic index increase of 0.1.
§For a crossclamp time increase of 30 minutes.
Table VII. Valve related complications
Major (fatal) Rate ± SE 
/minor* (%/pt-y)
Anticoagulant-related bleeding 4 (2)/1 0.09 ± 0.03
Embolism 27 (4)/55 1.43 ± 0.16
Endocarditis 34 (7†) 0.59 ± 0.10
Tissue failure 258 (13†) 4.51 ± 0.28
Redo valve replacement
For endocarditis 15 (0)
For tissue failure 136 (14)
Total 151 (14) 2.64 ± 0.21
SE, Standard error.
*Number of events.
†Excluding death after redo valve replacement.
Table VIII. Independent determinants for embolism
b (SE) OR P value
Patient age ‡ 50 y 0.99 (0.30) 2.69 .0008
Aortic regurgitation 0.71 (0.27) 2.03 .009
Hypertension 0.81 (0.34) 2.25 .02
Harvest time ‡ 96 h 1.11 (0.40) 3.03 .03
b, Regression coefficient; SE, standard error; OR, odds ratio (see text).
3 risk factors (aortic regurgitation, hypertension, har-
vest time ‡ 96 hours) of Table VIII had an incidence of
first stroke (n = 9) of 0.23%/pt-y (95% CL: 0.08%-
0.38%/pt-y); 203 patients with 1 or 2 (no one had all 3)
of the other 3 risk factors had a rate of 0.62%/pt-y (95%
CL: 0.25%-0.99%/pt-y).
Endocarditis. Twenty-year freedom from allograft
endocarditis (Table VII) was nearly 90% (Fig 4). The
independent risk factors are shown in Table IX. An
allograft donor who was 10 years or more older than
the patient was a risk factor and was related to a 20-
year freedom from endocarditis of 83% ± 4% (n = 173)
compared with 93% ± 1% for a lesser age difference (n
= 445; P < .01). “Other” as a limiting symptom (see
Table I) was more prevalent (29%) among the 52
patients primarily operated on for active endocarditis
than in the remaining 566 patients (3%; P < .0001).
Primary tissue failure. The 10- and 20-year freedoms
from failure were 62% ± 3% and 18% ± 3%, respec-
tively (Fig 4). The hazard (instantaneous failure rate)
was 2.4%/y during the first 5 years after the operation,
6.5%/y for the next 5 years, 11.1%/y for the eleventh
through fifteenth years, 14.0%/y for the sixteenth
through twentieth years, and 3.3%/y for the twenty-first
through twenty-fifth years, with mean and median fail-
ure times of 13.1 and 12.5 years, respectively. At end-
of-study, 30 patients (5%) with a failing allograft had
no related symptoms, 79 (31%) had medically treated
congestive heart failure, 13 (5%) had died, and 136
(53%) had undergone a first redo AVR, of whom 14
died during the first 30 postoperative days.
The 10- and 15-year freedoms from failure for the
viable versus the antibiotic-sterilized allografts
(patients operated on for endocarditis or ascending aor-
tic aneurysm/dissection excluded) were 71% ± 7% and
71% ± 7% (n = 115) versus 61% ± 3% and 32% ± 3%
(n = 416; P < .05). Failure was less common in patients
who had an allograft root replacement than in those
with pure subcoronary implantation, whereas failure
was more common in those with a root tailoring (Fig
5). The independent risk factors for primary tissue fail-
ure are shown in Table X. The difference between
donor and patient age was the most significant risk fac-
tor, as illustrated in Fig. 6. Donor age above 65 years
was a determinant in its own right, almost doubling the
risk of failure (Table X); increasing implantation time
(from harvest to AVR; Table II) also had a strong influ-
ence. The freedom from failure estimated by the Cox
model for a “best” to a “worst” risk subset for a patient
aged 70 years and one aged 30 years are depicted in Fig
7. The 70-year-old patient (A curves) had a consider-
ably better freedom from failure for each risk subset
than the 30-year-old patient (B curves). The difference
from the A1 to A2 curves (and corresponding B1 to B2
curves) indicates the influence of viable versus antibi-
otic-sterilized allograft; the difference from A2 to A3
curves (and the corresponding B2 and B3 curves) illus-
trates the impact of increasing donor age from 30 to 67
years; and the A4 and B4 curves include the remaining
risk factors of Table X. A 70-year-old patient with a
viable allograft from a 65-year-old donor (oldest viable
valve donor) and no other risk factors would have 10-
and 20-year freedoms from failure of 71% and 20%,
respectively; the figures would be 49% and 3%, respec-
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Table IX. Independent determinants for endocarditis
b (SE) OR P value
Limiting symptom “other” 1.44 (0.42) 4.22 .008
Male sex 1.20 (0.53) 3.32 .02
Donor ‡ 10 y older than patient 0.86 (0.34) 2.36 .01
b, Regression coefficient; SE, standard error; OR, odds ratio (see text).
Table X. Independent determinants for tissue failure
b (SE) OR P value
Donor minus patient age* 0.020 (0.004) 1.22† <.0001
Implantation time* 0.001 (0.0003) 1.11‡ .002
Donor age > 65 years 0.56 (0.20) 1.75 .006
Cardiothoracic index >0.55 0.33 (0.13) 1.39 .01
Diabetes mellitus 0.96 (0.46) 2.61 .04
Previous myocardial 0.65 (0.31) 1.92 .04
infarction
b, Regression coefficient; SE, standard error; OR, odds ratio (see text).
*Entered with continuous value.
†For a donor minus patient age increase of 10 years.
‡For an implantation time increase of 100 hours.
Table XI. Independent determinants for redo valve
replacement
b (SE) OR P value
Donor minus patient age* 0.023 (0.001) 1.26† .001
Patient age* –0.026 (0.008) 0.77† .002
Implantation time* 0.0014 (0.0004) 1.15‡ .002
Marfan syndrome 1.46 (0.48) 4.31 .002
Diabetes mellitus 1.91 (0.60) 6.75 .002
Root replacement –1.03 (0.42) 0.36 .01
AV block grade 1-3 0.89 (0.36) 2.44 .01
Aortic root tailoring§ 0.46 (0.22) 1.58 .03
b, Regression coefficient; SE, standard error; OR, odds ratio (see text).
*Entered with continuous value.
†For a donor minus patient age increase or patient age increase of 10 years.
‡For an implantation time increase of 100 hours.
§Before subcoronary implantation of allograft.
tively, for a 30-year-old patient (see A1 and B1 curves
of Fig 7).
Redo valve replacement. Table VII summarizes data
of the first reoperation, and the cumulative freedoms
are depicted in Fig. 4. The independent risk factors are
given in Table XI. Donor minus patient age again was
a strong risk factor, but “decreasing” patient age was
also influential. The latter was related to the increasing
failure rate of young patients but also to a certain reluc-
tance to reoperate on a very old patient with a failing
allograft. Root replacement independently reduced the
risk of reoperation, whereas root tailoring to accommo-
date a subcoronary implantation increased the risk
(Table XI, Fig 8).
The valve substitute of the 151 first redo AVRs (Table
VII) included allografts in 50%, mechanical valves in
46%, and xenografts in 4%. The 10-year survival after
first redo was 72% ± 6% in the 75 patients who
received a second allograft and 56% ± 6% in the 76
who received a mechanical or xenograft valve (P <
.05). Their ages at first redo operation were 50 ± 14 and
55 ± 14 years, respectively (P < .05). A total of 136
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Fig 5. Cumulative freedom from tissue failure in relation to allograft procedure; see legends to Fig 3 for identi-
fication of procedure groups. Cumulative freedoms ± 1 SE (number of patients at risk) are given at 10, 15, and
20 years.
Fig 6. Cumulative freedom from tissue failure in relation to age difference between allograft donor and patient.
D-P Age, Donor minus patient age. Cumulative freedoms ± 1 SE (number of patients at risk) are given at 10 and
20 years.
patient had only 1 redo AVR, 14 had 2 such operations,
and 1 patient had 3.
Discussion
This study has served to document the “true” long-
term pattern of performance of aortic valve allografts
over a period of up to 27 years and has identified sev-
eral patient-, allograft-, and procedure-related factors
that could influence patient outcome parameters.
Several previous reports from our center4,5,13,15 and oth-
ers6,7 were based on maximum follow-up periods vary-
ing around 10 to 15 years for current models of allo-
grafts. We believe that this underestimates the
incidence of complications and that the true results are
better represented by longer follow-up times.
A major advantage of the allograft as an aortic valve
substitute is the restoration of blood flow in the aortic
root, sinuses, and coronary ostia to normal or near nor-
mal. The normal aortic valve is a highly complex and
sophisticated structure that starts opening and closure
preceding hemodynamic events.23 The hemodynamic
advantage translates into pressure gradients across allo-
grafts, which are usually negligible and significantly
lower than the gradients across stented xenografts and
modern disc valves.24,25 The impact may be a more
complete regression of left ventricular hypertrophy
after a successful AVR with an allograft.24 Complete
regression of hypertrophy is a main factor in keeping
the left ventricle well functioning in the long term,26
which may be an important determinant of long-term
survival.18 The current interest in unstented xenografts
in general and in patients with a small aortic root in
particular is understandable, particularly given the lim-
ited availability of allografts.
The hemodynamic advantage of the allograft can be
exploited only if other allograft-related factors do not
impair long-term survival. The present method of
antibiotic sterilization4,12 has significantly improved
results compared with earlier methods of sterilization
and preservation.10 The present viable allograft5 and
the viable cryopreserved allograft,7 both harvested
from live donors, may have improved results further.
A first concern regarding allograft AVR is the more
complex implantation technique compared with those
needed for stented xenografts or mechanical valves.
However, the present early mortality compares favor-
ably with results of numerous published AVR series,
both those spanning the same time period as the present
series and more recent studies. Furthermore, we identi-
fied widely known risk factors for early mortality, in
terms of both associated surgical procedures and
patient-related factors. Notably, a full root replacement
with reimplantation of the coronary arteries did not
entail increased risk.
During a more than 25-year follow-up with an aver-
age starting age of 51 years, normal epidemiologic risk
factors and death rates are in effect.18 Age as an inde-
pendent risk factor needs no explanation, whereas the
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Fig 7. Estimated freedoms from tissue failure using a Cox regression model; see text and Table X. A1, A2, A3,
and A4 curves, A 70-year-old patient, and –A1, donor age of 30 years, viable allograft with implantation time of
48 hours, and no other risk factors (Table X); A2, similar to the preceding but with an antibiotic-sterilized allo-
graft and an implantation time of 120 hours; A3, similar to the preceding but with a donor age of 67 years; and
A4, similar to the preceding but with all other risk factors of Table X. B1, B2, B3, and B4 dotted curves, like A1,
A2, A3, and A4 curves, but with a 30-year old patient. Estimated freedoms are given at 10 and 20 years. 
influence of male sex may be related to a generally
shorter life span of men compared with women. Other
independent risk factors for late mortality of the pres-
ent study underscored the influence of advanced heart
disease before the operation, in agreement with other
long-term studies spanning the same time period.11,27
The present long-term survival was comparable with
the survivals of a predominantly biologic27 and a pre-
dominantly mechanical AVR series,18 both with more
than 20 years of follow-up.
In the current series, valve characteristics including
method of preparation and insertion appeared to have
an important influence on survival. The viable allograft
and root replacement were associated with better long-
term survival than the antibiotic-sterilized allograft and
subcoronary implantation. The frequency of root
replacement increased during the 25 years of surgery.
As a result, more than half were done with a viable
valve, indicating that the 2 determinants were compli-
mentary in their beneficial influence on survival. Our
results regarding root replacement confirmed previous
findings.5,14 The beneficial influence of a viable allo-
graft on long-term survival was probably explained by
its lesser tendency to failure (as was the case for root
replacement) than the antibiotic-sterilized allograft.
Equally important was the finding that donor age was
related to late mortality; this was obviously a reflection
of increased risk of both endocarditis and primary tis-
sue failure of an allograft from elderly donors.
Allografts and other biologic valves are generally
considered nonthrombogenic. However, in this series
we have observed a definite incidence of thromboem-
bolic complications. It should be recognized that there
are normal rates of thromboembolic phenomena such
as stroke in the general background population.21,22
The internationally accepted guidelines for reporting
thromboembolism after heart valve replacement16
state, in essence, that a systemic vascular event should
be recorded as embolic unless there is proof of throm-
bosis (or hemorrhage), indicating that the rate of valve-
related embolism will be overestimated. During the
present very long follow-up, the rate of embolism was
1.4%/pt-y, which is lower than the average for mechan-
ical valves, despite the absence of anticoagulant treat-
ment in the vast majority of the present patients. In a
recently published paper, a current stented pericardial
xenograft aortic valve was associated with an embolic
rate of 1.6%/pt-y.28 However, using published tabulat-
ed age- and sex-specific rates of stroke of a general
United Kingdom population,21 we were able to calcu-
late22 the stroke incidence of a background population
with the same sex and age composition as the present
patients: the background incidence did not differ from
the observed (embolic, hemorrhagic, thrombotic)
stroke rate of our patients. Furthermore, systemic
hypertension and age, being the predominant risk fac-
tors for stroke in the general population,22 were also
independent determinants of embolism in the present
patients. Our data thus confirm that the allograft in gen-
eral is not thrombogenic. The exception may be the
cadaver valve that is harvested too long after death of
the donor.
The present 25-year freedom from endocarditis of
89% indicates that the allograft is resistant to infection.
A 10-year freedom of 97% after allograft AVR in pros-
thetic valve endocarditis29 strongly supports that
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Fig 8. Cumulative freedom from redo valve replacement in relation to allograft procedure; see legend to Fig 3 for
identification of procedure groups. Cumulative freedoms ± 1 SE are given at 10 and 20 years. 
notion. The allograft, especially used as a full root
replacement, is recommended in complex aortic valve
endocarditis, especially with destruction of the aortic
root.29 The present incidence of endocarditis was com-
parable with the average of reported figures for
mechanical valves and somewhat lower than the inci-
dence associated with stented xenograft aortic valves.
The latter was directly confirmed by Agnihotri,
McGiffin, Galbraith, and O’Brien.30 Interestingly, we
observed that donor-patient age mismatch of 10 years
or more independently increased the risk of endocardi-
tis. This finding needs to be confirmed in future stud-
ies, and similarly the underlying mechanisms require
further research.
The main drawback of allografts and of any other bio-
logic valves is their limited durability. It is important to
emphasize that length of follow-up may have a pro-
found influence on estimated freedoms from primary
tissue failure. In the present more than 25-year follow-
up series, with a significant number of patients at risk in
the long term, the hazard of failure seemed to be espe-
cially high during 16 to 20 years after the operation
before it seemed to return to a phase of low and constant
risk. In a previous publication from the present center
with a maximum follow-up of just above 15 years, the
10- and 15-year freedoms from failure of the antibiotic-
sterilized allograft were 77% and 48%, respectively4; in
the present series the figures were 61% and 32%,
respectively. Similarly, with 14 years of follow-up we
previously reported an 89% 10-year freedom from fail-
ure for the viable allograft5; in the present study, with 17
years of follow-up, the 10-year freedom was 71%. The
present article may thus give a picture close to the real
failure characteristics of allograft aortic valves, at least
as regards the antibiotic-sterilized valve.
Primary tissue failure is not a trivial complication, and
any measure that can reduce the incidence is directly
warranted. The technical surgical procedure seemed to
influence the risk of failure. A full root replacement was
associated with a low incidence of failure, whereas aor-
tic root tailoring to accommodate a subcoronary implan-
tation seemed to be associated with a very high failure
rate between 5 and 10 years after the operation. Root
replacement and root tailoring had direct beneficial and
adverse influences, respectively, in the multivariable
model for redo AVR that was undertaken primarily
because of failure. These findings could be explained by
the fact that the essential feature of root replacement is
that the anatomic integrity of the valve is perfectly
maintained from root to sinotubular junction. At the
other extreme stands the attempt of the surgeon to recre-
ate the anatomy by first shaping and tailoring the native
root and then stitching the scalloped allograft in place in
the subcoronary position with a 2-line freehand tech-
nique. Others have also observed the increased failure
tendency associated with root tailoring,8 as well as the
favorable influence of root replacement.5,31,32
Young patient age is a time-proven widely known
risk factor for degenerative failure of porcine33 and
pericardial28 xenografts, as well as of allografts.5,8,34 In
the present study, patient age played a significant role
but donor age was an even stronger determinant of fail-
ure. The 2 variables were interrelated: the donor-patient
age match or mismatch appeared to be the dominant
factor. Furthermore, the very old allograft (donor age >
65 years) in its own right significantly increased the
risk of failure. It has previously been reported from the
present institution that donor age of more than 65 years
was related to early allograft failure.35 Time from allo-
graft harvest to implantation was also directly related to
risk of failure. Donor age, donor minus patient age, and
implantation time were all significantly higher for the
antibiotic-sterilized allograft than for the viable valve.
The former factors may thus in part explain the better
freedom from failure of the viable valves.
The risk factors for redo AVR reflected the multi-
variable models for endocarditis and primary tissue
failure. Interestingly, diabetes mellitus adversely influ-
enced primary tissue failure and consequently also
redo AVR. With a relation to “general tissue weak-
ness” of diabetes mellitus, this finding may pinpoint
factors of the tissue in which the allograft rests. The
remaining risk factors, high cardiothoracic index, pre-
vious myocardial infarction, and atrioventricular
block, indicate a deleterious influence of preoperative-
ly impaired heart status. It has previously been shown
that impaired left ventricular function was related to
increased intravascular hemolysis in patients with aor-
tic ball valves36 and with a modern bileaflet disc
valve.25 A regionally or globally malfunctioning pump
may give rise to higher turbulent shear forces in the
flow profiles of mechanical valves, which may trau-
matize erythrocytes18,25,36 as well as the leaflet edges
of an allograft. A dilated left ventricle (and root) may
also add to difficulties of restoring the anatomic
integrity of the valve and left ventricular outflow tract,
especially in a subcoronary implantation.
In conclusion, our study has defined the long-term
behavior of the allograft both in terms of survival and
complications, and it has identified several factors that
could influence these parameters and therefore be of
clinical relevance. During the very long follow-up of
the present study, the hazard of primary tissue failure
“re-entered” a phase of low and constant risk first after
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20 years. The failure characteristics of the present allo-
graft series may thus indicate the true behavior of the
allograft, inasmuch as studies with a shorter follow-up
significantly underestimated the failure rate. Our data
suggest that allograft AVR can give acceptable results
for up to 25 years. Furthermore, the late results can be
improved by the use of a viable allograft, by matching
patient and donor age, by avoiding the old donor, and
by more liberal use of free root replacement with reim-
plantation of the coronary ostia rather than tailoring the
root to accommodate a subcoronary implantation. It is
hoped that our findings will help to optimize the long-
term results of allograft AVR.
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Discussion
Dr Mark F. O’Brien (Brisbane, Australia). Dr Lund, I
congratulate you and your colleagues, specifically Sir Magdi
Yacoub, for the valuable analysis of your allograft experi-
ence. You highlight the importance of donor age, reasonably
short donor death–to–implantation time (although you talk of
harvest-to-implantation time), and a better valve matching
with the technical implantation of the root replacement. 
Eleven years ago in 1987 at this very meeting we present-
ed and published from our Brisbane experience, which is now
over 1000 allografts, the incremental risk factors of reopera-
tion for degeneration—younger age of patient at AVR and
older age of donor. You have gone further, to focus on the
additional factors that influence the quality of the valve, fac-
tors that affect viability and preservation of the tissue matrix.
We have been saying for some decades now that a valve
should be implanted early or cryopreserved as early as possi-
ble. Our mean time to preservation is 15 hours from donor
death. We have shown clinically a marked difference in the
durability between early cryopreserved valves and the antibi-
otic-sterilized valves that stayed in the refrigerator for days or
weeks. The freedom from structural deterioration and reoper-
ation at 20 years in our experience is 60%. 
I read your manuscript as carefully as I could. You would
be surprised to know that we would not use 51% of your
homovital valves and 78%, at least, of your antibiotic-steril-
ized valves because the time from death to implantation is too
long. This may explain why our freedom from primary tissue
failure in the whole cohort, without subdivision of the cohort,
was 60% at 20 years, whereas your very best results are in the
70-year-old patient with a 30-year-old donor, giving 10- and
20-year freedoms from tissue failure of 91% and 64%. 
I have a number of questions. A homograft is an excellent
valve at 10 years, it is a very good valve at 15 years, but it is
far from optimal at 20 years. Yet you make the statement that
the homograft AVR can give acceptable results for up to 25
years. I would not accept those results out to 25 years. We do
not accept our own results, which really are better than yours.
There are many avenues for improvement, on some of which
you have focused. 
My first question is this: Do you think the homograft is an
acceptable device to 25 years? 
What was the time from donor death to cryopreservation?
Could you expand on the influence of patient age on reop-
eration, particularly in that younger age group? We are begin-
ning to learn of the poor results in infants and teenagers, but
what are your thoughts on the reasons why the results are not
as good in these younger recipients? 
Why do you think endocarditis was more prevalent with
the older donor valve? Is it because degeneration occurs more
quickly? 
What modifications have you made for your collection and
harvesting protocol, particularly in regard to the cutoff age of
the donor? 
Last, what happens if you cannot implant the valve within
that magic homovital time period of 72 hours? Do you cry-
opreserve it, which we would regard as late cryopreservation? 
Mr Lund. Thank you, Dr O’Brien. With regard to the com-
parison with your own results, I think there are two important
things that should be said. First, I noticed from a previous
publication from your center that less than 30% of your
patients receive a homograft valve, so yours is a selected
series whereas ours is not. The homograft was the valve of
choice at Harefield Hospital, and that may significantly influ-
ence results. 
Second, as your follow-up has just passed 20 years, at least
with the results you have published, we might suspect that
with a follow-up closer to 30 years, your 20-year results may
not look as good as they do today. We have noticed with pre-
vious publications from Harefield, with the antibiotic-steril-
ized homograft, that the estimated 15-year freedom reported
in 1985 and in 1990 has been successively dropping down to
current figures with an almost 30-year follow-up. Selection
of patients most certainly will influence long-term results and
so will length of follow-up. 
I do not know the answer to your question about the time
from harvest to cryopreservation of the 12 valves.
You asked about the possible mechanism of an increased
tendency for endocarditis for the old donor valve. In our
analyses, the donor-patient age match or mismatch was the
important factor. The worst subset seemed to be old donor in
young patient. We can only speculate about the mechanism.
Further research certainly is needed. Maybe the donor valve
from an elderly patient is more prone to degeneration and
weakness of tissues and therefore more susceptible to endo-
carditis, but that is only speculative. 
Regarding implantation of homovital valves, if the valve is
still in the refrigerator after 72 hours, we will use it.
Obviously we prefer to implant the valve as soon as possible
after harvest from the viable donor, and preferably within 48
hours, but that is something that needs to be tightened up in
our center. 
Matching of patient and donor age is going to be relevant
in the future, but we have not done it so far. However, this
analysis is quite new.
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Dr Charles A. Yankah (Berlin, Germany). I rise to congrat-
ulate Dr Lund and Sir Magdi Yacoub for this excellent clinical
study. Twenty-five years of homograft valve function is impres-
sive, and it also provides important information for us surgeons
with regard to how to speak to the relatives and patients.
We have implanted more than 250 homografts in the aortic
position, subcoronary and also root replacement. We define
our homovital valves as those homografts harvested during
our transplant program and preserved within 24 hours, maxi-
mum 35 hours. We made prostacyclin studies, which indicat-
ed cellular viability in about 20% of these valves at the time
of implantation. The rest of them, however, possessed no
endothelial cells. The viability of the homografts was defined
in relation to structural viability, that is, those without
endothelial cells but with some living fibroblasts that will not
survive long after implantation.
My question is this: What is the cellular viability definition
in your homovital valves? Can you derive your experience
from the results whether the antibiotic treatment in the
homovital group had an impact on the results of the implan-
tation technique such as sizing, root replacement, and the
subcoronary technique? 
Mr Lund. Regarding viability of the valve: Will viability
influence long-term results? In this respect, we would all
think in terms of major histocompatibility antigens. Results on
research in that field are conflicting. Results from Harefield
and also from Holland seem to indicate that major anti-
genicity is not a factor in the viable homograft, where-
as results from Dr O’Brien’s group tend to indicate the
opposite. 
With regard to technical procedure, we do not distinguish
between a homovital or an antibiotic-sterilized homograft.
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